Tag
M&A
10 articles
M&A Value Falls 10% in Q3 as Rate Expectations Fail to Materialize
A 10 percent year-on-year decline in announced deal value signals structural headwinds that persist despite dealmakers' optimism for a record year.
Warburg Pincus Raises Ingenia Bid to $5.25/Share; INA Jumps 6.67%
Private equity firm escalates takeover offer for Australian communities operator to $2.14 billion, third increase in bidding war
Vantora Closes $100M to Build Custom AI Startups for Enterprise Clients
The startup builder secured its first outside funding to develop proprietary physical AI ventures that enterprise partners can own outright, targeting industrial and energy sectors.
Stripe's $7.5B OpenRouter Bet: The Toll Road Through AI Infrastructure
Nine companies chased the AI routing startup. Stripe won by recognizing that metering every enterprise's AI consumption is worth more than processing its payments.
PE's Exit Crisis: 33,575 Unsold Companies Lock Up Limited Partner Cash
Private equity's portfolio backlog doubled to 33,575 companies in a decade, blocking distributions to pension funds and endowments while delaying carried-interest payouts to Apollo, Blackstone, KKR and Carlyle
AstraZeneca Explored Acquisition of Bristol Myers Squibb in $400 Billion Deal
A combination would create one of the world's largest drugmakers and expand AstraZeneca's footprint in the United States.
Louisville Bidder Presses Brown Family to Reopen Rejected Takeover
The Louisville firm is pushing for direct negotiations after its initial offer failed to win Brown family support, renewing a deal process stalled by shareholder resistance
B2C2 Sale Talks Stall at $1 Billion Valuation
SBI Holdings' crypto market maker B2C2 held talks with multiple suitors over 18 months, but a $1 billion-plus price tag killed every deal.
TikToker's Spirit Airlines Bid: Social Media's New M&A Frontier or Fleeting Trend?
A viral TikTok campaign to acquire the distressed Spirit Airlines after its operational collapse highlights the growing influence of social media on capital markets and the potential for retail investor-driven corporate action.
UCB $2.2 Billion Buy Signals M&A Resilience Amid Stable Rates
Belgian pharma group UCB's substantial acquisition of Candid Therapeutics underscores how prevailing interest rate conditions and broader economic stability are shaping corporate M&A strategies and capital deployment.